-
1.发明授权Composition and method for producing an immune response against tumor-related antigens 有权用于产生针对肿瘤相关抗原的免疫应答的组合物和方法公开(公告)号：US07414108B2
公开(公告)日：2008-08-19
申请号：US10772856
申请日：2004-02-04
申请人： Reiner Laus , Curtis L. Ruegg , Michael H. Shapero , Demao Yang
发明人： Reiner Laus , Curtis L. Ruegg , Michael H. Shapero , Demao Yang
IPC分类号： C07K5/10
CPC分类号： A61K39/0011 , A61K38/00 , A61K39/00 , C12N9/16 , C12N2799/022 , C12N2799/026
摘要： Disclosed are a novel prostatic acid phosphatase and corresponding coding region derived from mouse. Also disclosed is a method of producing an immune response against an autologous polypeptide tumor antigen by immunizing a subject with a xenogeneic polypeptide antigen, either alone, as part of a viral antigen construct, or as part of a pulsed dendritic cell preparation.
摘要翻译： 公开了一种新型前列腺酸性磷酸酶及其衍生自小鼠的相应编码区。 还公开了通过用异种多肽抗原单独免疫受试者作为病毒抗原构建物的一部分或作为脉冲树突状细胞制剂的一部分来产生针对自体多肽肿瘤抗原的免疫应答的方法。
-
2.发明授权Alloreaction-associated antigen (ARAG): a novel member of the immunoglobulin gene superfamily 失效同种异体反应相关抗原（ARAG）：免疫球蛋白基因超家族的新成员
公开(公告)号：US5646251A
公开(公告)日：1997-07-08
申请号：US497025
申请日：1995-06-30
申请人： Curtis L. Ruegg , Alberto Rivas , Reiner Laus , Edgar G. Engleman
发明人： Curtis L. Ruegg , Alberto Rivas , Reiner Laus , Edgar G. Engleman
IPC分类号： A61K38/00 , C07K14/705 , C07K16/28 , C07K7/00 , C12N15/00
CPC分类号： C07K16/2803 , C07K14/70503 , A61K38/00 , C07K2317/73
摘要： The invention provides purified ARAg polypeptides, antibodies against ARAg polypeptides and nucleic acids encoding ARAg polypeptides. Also provided are methods of diagnosis and treatment using the same. ARAg polypeptides are typically present on the surface of alloantigen-activated CD8.sup.+ T-cells, monocytes, granulocytes and peripheral dendritic cells, and substantially absent on resting T-cells, mitogen-activated CD8.sup.+ T-cells, B-cells, erythroid cell lines, myelomonocitic cell lines, EBV-LCL cell lines and fibroblastoid cell lines. An exemplary ARAg polypeptide, termed ARAg-h-1, has a signal sequence, seven variable-type immunoglobulin-like domains, a transmembrane domain and an intracellular domain.
摘要翻译： 本发明提供纯化的ARAg多肽，抗ARAg多肽的抗体和编码ARAg多肽的核酸。 还提供了使用其进行诊断和治疗的方法。 ARAg多肽通常存在于异源抗原激活的CD8 + T细胞，单核细胞，粒细胞和外周树突细胞的表面上，并且在静息T细胞，丝裂原活化的CD8 + T细胞，B细胞，红细胞系， 骨髓单核细胞系，EBV-LCL细胞系和成纤维细胞系。 称为ARAg-h-1的示例性ARAg多肽具有信号序列，七个可变型免疫球蛋白样结构域，跨膜结构域和细胞内结构域。
-
公开(公告)号：US5998599A
公开(公告)日：1999-12-07
申请号：US883070
申请日：1997-06-27
申请人： Curtis L. Ruegg , Reiner Laus , Edgar G. Engleman
发明人： Curtis L. Ruegg , Reiner Laus , Edgar G. Engleman
IPC分类号： G01N33/574 , A61K48/00 , C07K14/47 , C07K14/705 , C07K14/71 , C07K16/28 , C12N1/21 , C12N5/10 , C12N15/09 , C12N15/18 , C12N15/12 , C12N15/63
CPC分类号： C07K14/4703 , C07K14/705 , C07K14/71 , A61K48/00
摘要： Disclosed is a novel gene and growth arrest gene product encoded by the gene. Expression of the growth arrest gene B4B results in inhibition of cellular proliferation. The gene and gene product serve as markers of cancerous or pre-cancerous conditions, and as markers of immune states.
摘要翻译： 公开了由该基因编码的新基因和生长停滞基因产物。 生长停滞基因B4B的表达导致细胞增殖的抑制。 该基因和基因产物用作癌症或癌前病症的标志物，并作为免疫状态的标志物。
-
公开(公告)号：US09956435B2
公开(公告)日：2018-05-01
申请号：US13141935
申请日：2009-12-28
CPC分类号： A61Q19/08 , A61K8/64 , A61K2800/592 , A61K2800/91
摘要： This invention provides novel injectable compositions comprising botulinum toxin that may be administered to a subject for various therapeutic, aesthetic and/or cosmetic purposes. The injectable compositions contemplated by the invention exhibit one or more advantages over conventional botulinum toxin formulations, including reduced antigenicity, a reduced tendency to undergo unwanted localized diffusion following injection, increased duration of clinical efficacy or enhanced potency relative, faster onset of clinical efficacy, and/or improved stability.
-
5.发明申请公开(公告)号：US20120196349A1
公开(公告)日：2012-08-02
申请号：US13394506
申请日：2010-10-20
申请人： Curtis L. Ruegg
发明人： Curtis L. Ruegg
IPC分类号： C12N9/52
摘要： Methods and systems for chromatographically purifying a botulinum neurotoxin are provided. These methods and systems allow for efficient purification of a non-complexed form of the botulinum neurotoxin in high purity and yield that can be used as an active ingredient in pharmaceutical preparations.
摘要翻译： 提供了色谱纯化肉毒杆菌神经毒素的方法和系统。 这些方法和系统允许以高纯度和产率有效纯化非络合形式的肉毒杆菌神经毒素，其可用作药物制剂中的活性成分。
-
公开(公告)号：US20100168023A1
公开(公告)日：2010-07-01
申请号：US12647677
申请日：2009-12-28
IPC分类号： A61K38/16 , A61K8/64 , A61P25/14 , A61P25/00 , A61P27/02 , A61P19/02 , A61P13/06 , A61P11/02 , A61P17/10 , A61P21/02 , A61P17/00 , A61P5/00 , A61Q19/08
CPC分类号： A61Q19/08 , A61K8/64 , A61K2800/592 , A61K2800/91
摘要： This invention provides novel injectable compositions comprising botulinum toxin that may be administered to a subject for various therapeutic, aesthetic and/or cosmetic purposes. The injectable compositions contemplated by the invention exhibit one or more advantages over conventional botulinum toxin formulations, including reduced antigenicity, a reduced tendency to undergo unwanted localized diffusion following injection, increased duration of clinical efficacy or enhanced potency relative, faster onset of clinical efficacy, and/or improved stability.
摘要翻译： 本发明提供包含肉毒杆菌毒素的新型可注射组合物，其可以以各种治疗，美学和/或美容目的施用于受试者。 本发明预期的可注射组合物相对于常规的肉毒杆菌毒素制剂显示出一个或多个优点，包括降低的抗原性，注射后经历不想要的局部扩散的倾向降低，临床疗效持续时间增加或相对增强的效力，临床疗效的更快发作，以及 /或改进的稳定性。
-
7.发明申请Methods And Kits For Topical Application, Removal, And Inactivation Of Therapeutic Or Cosmetic Toxin Compositions 审中-公开治疗或化妆品毒素组合物的局部应用，去除和灭活的方法和试剂盒公开(公告)号：US20120294844A1
公开(公告)日：2012-11-22
申请号：US13334283
申请日：2011-12-22
申请人： Jacob M. Waugh , Curtis L. Ruegg
发明人： Jacob M. Waugh , Curtis L. Ruegg
CPC分类号： C12N1/36 , A61K8/0208 , A61K8/20 , A61K8/29 , A61K8/66 , A61K38/4893 , A61K2800/81 , A61Q19/08
摘要： This invention relates to methods and kits for safely removing and inactivating topical therapeutic or cosmetic compositions. The methods and kits according to the invention are particularly well suited for removing and inactivating highly toxic substances.
摘要翻译： 本发明涉及用于安全地去除和灭活局部治疗或化妆品组合物的方法和试剂盒。 根据本发明的方法和试剂盒特别适用于去除和灭活高毒性物质。
-
公开(公告)号：US09340587B2
公开(公告)日：2016-05-17
申请号：US12824118
申请日：2010-06-25
CPC分类号： A61K38/4893 , A61K8/022 , A61K8/4946 , A61K8/4973 , A61K8/4993 , A61K8/60 , A61K8/602 , A61K8/64 , A61K8/66 , A61K8/84 , A61K8/90 , A61K9/14 , A61K9/19 , A61K39/08 , A61K47/22 , A61K47/26 , A61K47/34 , A61K47/42 , A61Q19/008 , A61Q19/08 , C07K14/33 , C12Y304/24069 , Y02A50/469
摘要： This invention relates to botulinum toxin formulations that are stabilized without the use of any proteinaceous excipients. The invention also relates to methods of preparing and using such botulinum toxin formulations.
摘要翻译： 本发明涉及在不使用任何蛋白质赋形剂的情况下稳定的肉毒杆菌毒素制剂。 本发明还涉及制备和使用这种肉毒杆菌毒素制剂的方法。
-
公开(公告)号：US20120107361A1
公开(公告)日：2012-05-03
申请号：US13380131
申请日：2010-06-25
摘要： This invention relates to botulinum toxin formulations that are stabilized without the use of any proteinaceous excipients. The invention also relates to methods of preparing and using such botulinum toxin formulations.
摘要翻译： 本发明涉及在不使用任何蛋白质赋形剂的情况下稳定的肉毒杆菌毒素制剂。 本发明还涉及制备和使用这种肉毒杆菌毒素制剂的方法。
-
公开(公告)号：US20110268765A1
公开(公告)日：2011-11-03
申请号：US13141935
申请日：2009-12-28
CPC分类号： A61Q19/08 , A61K8/64 , A61K2800/592 , A61K2800/91
摘要： This invention provides novel injectable compositions comprising botulinum toxin that may be administered to a subject for various therapeutic, aesthetic and/or cosmetic purposes. The injectable compositions contemplated by the invention exhibit one or more advantages over conventional botulinum toxin formulations, including reduced antigenicity, a reduced tendency to undergo unwanted localized diffusion following injection, increased duration of clinical efficacy or enhanced potency relative, faster onset of clinical efficacy, and/or improved stability.
摘要翻译： 本发明提供包含肉毒杆菌毒素的新型可注射组合物，其可以以各种治疗，美学和/或美容目的施用于受试者。 本发明预期的可注射组合物相对于常规的肉毒杆菌毒素制剂显示出一个或多个优点，包括降低的抗原性，注射后经历不想要的局部扩散的倾向降低，临床疗效持续时间增加或相对增强的效力，临床疗效的更快发作，以及 /或改进的稳定性。
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.025 秒)
